Clinical trial
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry
NCT06979518 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 20, 2025
- Completion date
- April 22, 2026
- Enrollment
- 30 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.